- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06125951
Efecto de 10 mg de Xanaem sobre la demencia debida a la enfermedad de Alzheimer (XanaMIA)
Un ensayo de fase 2b, doble ciego, controlado con placebo, de grupos paralelos, de 36 semanas y de 2 brazos para evaluar la seguridad, tolerabilidad y eficacia de Xanamem® 10 mg al día en pacientes con demencia leve o moderada debida a la enfermedad de Alzheimer
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia
- ACW Investigative Site 106
-
Erina, New South Wales, Australia
- ACW Investigative Site 103
-
Kogarah, New South Wales, Australia
- ACW Investigative Site 102
-
Macquarie Park, New South Wales, Australia
- ACW Investigative Site 107
-
Newcastle, New South Wales, Australia
- ACW Investigative Site 111
-
-
Queensland
-
Birtinya, Queensland, Australia
- ACW Investigative Site 113
-
Chermside, Queensland, Australia
- ACW Investigative Site 105
-
-
South Australia
-
Bedford Park, South Australia, Australia
- ACW Investigative Site 114
-
Woodville South, South Australia, Australia
- ACW Investigative Site 110
-
-
Victoria
-
Carlton, Victoria, Australia
- ACW Investigative Site 115
-
Ivanhoe, Victoria, Australia
- ACW Investigative Site 101
-
Malvern, Victoria, Australia
- ACW Investigative Site 108
-
Parkville, Victoria, Australia
- ACW Investigative Site 112
-
-
Western Australia
-
Nedlands, Western Australia, Australia
- ACW Investigative Site 104
-
West Perth, Western Australia, Australia
- ACW Investigative Site 109
-
-
-
-
California
-
Carlsbad, California, Estados Unidos, 92011
- ACW Investigative Site 218
-
Sherman Oaks, California, Estados Unidos, 91403
- ACW Investigative Site 209
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- ACW Investigative Site 211
-
Englewood, Colorado, Estados Unidos, 80113
- ACW Investigative Site 208
-
-
Florida
-
Delray Beach, Florida, Estados Unidos, 33445
- ACW Investigative Site 203
-
Miami, Florida, Estados Unidos, 33176
- ACW Investigative site 201
-
New Port Richey, Florida, Estados Unidos, 34652
- ACW Investigative site 202
-
Orlando, Florida, Estados Unidos, 32803
- ACW Investigative site 204
-
The Villages, Florida, Estados Unidos, 32162
- ACW Investigative site 205
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30030
- ACW Investigative Site 207
-
-
New Jersey
-
Marlton, New Jersey, Estados Unidos, 08053
- ACW Investigative Site 206
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- ACW Investigative Site 214
-
Staten Island, New York, Estados Unidos, 10314
- ACW Investigative Site 219
-
-
Ohio
-
Dayton, Ohio, Estados Unidos, 45459
- ACW Investigative Site 210
-
Independence, Ohio, Estados Unidos, 44131
- ACW Investigative Site 217
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97225
- ACW Investigative Site 212
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- ACW Investigative Site 216
-
-
Texas
-
Austin, Texas, Estados Unidos, 78757
- ACW Investigative Site 220
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98007
- ACW Investigative Site 215
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Male or female aged 50 years or older, inclusive at the time of Screening.
-
Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:
- Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
- Mini-mental state examination (MMSE) score of 18 to 26
- Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
- Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
-
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
-
Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
-
Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
-
Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
-
Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion Criteria:
- Use of anti-amyloid or anti-tau antibody within 6 months.
- Diagnosis of a non-AD dementia including traumatic brain injury.
- Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
- Participation in another clinical trial of a drug or device
- Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
- Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
- Clinical diagnosis of Type I or Type II diabetes requiring insulin.
- Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
- Participants with a history of clinically significant drug abuse or addiction in the past 2 years
- Evidence or history of alcohol abuse
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Otros nombres:
|
|
Comparador de placebos: Placebo
Placebo tablet, to be administered orally once every morning with or without food |
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient. |
|
Experimental: Open label phase
Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
Periodo de tiempo: 36 weeks
|
Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
36 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Periodo de tiempo: 36 weeks
|
Incidence and severity of TEAEs |
36 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Global Program Lead, Actinogen Medical Ltd
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Trastornos neurocognitivos
- Tauopatías
- Enfermedades neurodegenerativas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Enfermedades hemic y linfáticas
- Enfermedad de Alzheimer
- Linfoma Folicular
- Demencia
- UE2343
Otros números de identificación del estudio
- ACW0009
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .